Keyword: Bristol-Myers Squibb (BMS)
News
19.10.2016
- The $2 billion initial public offering launched last week in Hong Kong by Chinese state-backed China Resources Pharmaceutical, the country’s second-largest drugmaker, attracted...
News
12.10.2016
- The newly developed Bristol-Myers (BMS) lung cancer drug Opdivo, a so-called checkpoint inhibitor that stimulates the immune system so that it can attack malignant tumours, has...
Chemistry & Life Sciences
13.06.2016
- Since the beginning of the 21st century, pharma M&A activity has exploded. Mergers and acquisitions, layoffs, and outsourcing of research and manufacturing have become common place...
News
06.06.2016
- The European Commission has granted approval for Novartis’ Afinitor (everolimus) for treating unresectable or metastatic, well-differentiated non-functional neuroendocrine tumors...
News
24.05.2016
- The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s (BMS) cancer drug, Opdivo, to treat classical Hodgkin Lymphoma (HL). The approval is the eighth for...
News
19.05.2016
- Bristol-Myers Squibb (BMS) and AbbVie’s cancer treatment Empliciti has received the green light in Europe to treat multiple myeloma, a blood cancer that develops in the bone marrow...
News
27.04.2016
- US regulators have given a breakthrough designation to Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) for treating head and neck cancer. This is the fifth breakthrough...
News
21.04.2016
- Non-profit group the Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug maker Pharco Pharmaceuticals have teamed up to launch a low-cost hepatitis C combination...
